New Perspectives on Overactive Bladder: Quality of Life Impact, Medication Persistency, and Treatmen

---

New Perspectives on Overactive Bladder: Quality of Life Impact, Medication Persistency, and Treatment Costs

C. Daniel Mullins, PhD;Leslee L. Subak, MD

July 15th 2005

ArticleINTRODUCTION

---

PARTICIPATING FACULTY

July 15th 2005

ArticleSUPPLEMENT CONTENT

---

Persistence With Overactive Bladder Pharmacotherapy in a Medicaid Population

Fadia T. Shaya, PhD, MPH;Steven Blume, MS;Anna Gu, MA;Teresa Zyczynski, PharmD, MBA, MPH;Zhanna Jumadilova, MD, MBA

July 15th 2005

ArticleREPORTS

---

The Impact of Urinary Incontinence on Quality of Life of the Elderly

Yu Ko, MS;Swu-Jane Lin, PhD;J. Warren Salmon, PhD;Morgan S. Bron, PharmD, MS

July 15th 2005

ArticleREPORTS

---

Safety and Tolerability of Tolterodine for the Treatment of Overactive Bladder in Adults

Richard G. Roberts, MD, JD;Alan D. Garely, MD;Tamara Bavendam, MD

July 15th 2005

ArticleREPORTS

---

Medical Costs After Initiation of Drug Treatment for Overactive Bladder: Effects of Selection Bias on Cost Estimates

Nicole M. Nitz, PhD;Zhanna Jumadilova, MD, MBA;Theodore Darkow,   PharmD;Jennifer R. Frytak, PhD;Tamara Bavendam, MD

July 15th 2005

ArticleREPORTS

---

Economic Impact of Extended-release Tolterodine versus Immediate-and Extended-release Oxybutynin Among Commercially Insured Persons With Overactive Bladder

Sujata Varadharajan, MS;Zhanna Jumadilova, MD, MBA;Prafulla Girase, MS;Daniel A. Ollendorf, MPH

July 15th 2005

ArticleREPORTS

---

Urinary Incontinence in the Nursing Home: Resident Characteristics and Prevalence of Drug Treatment

Zhanna Jumadilova, MD, MBA;Teresa Zyczynski, PharmD, MBA, MPH;Barbara Paul, MD;Siva Narayanan, MS, MHS

July 15th 2005

ArticleREPORTS

---

Treatment of Overactive Bladder: A Model Comparing Extended-release Formulations of Tolterodine and Oxybutynin

Eleanor M. Perfetto, PhD;Prasun Subedi, MS;Zhanna Jumadilova, MD, MBA

July 15th 2005

ArticleREPORTS